These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19079589)

  • 1. Non-natural and photo-reactive amino acids as biochemical probes of immune function.
    Gómez-Nuñez M; Haro KJ; Dao T; Chau D; Won A; Escobar-Alvarez S; Zakhaleva V; Korontsvit T; Gin DY; Scheinberg DA
    PLoS One; 2008; 3(12):e3938. PubMed ID: 19079589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
    Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
    Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.
    Chaise C; Buchan SL; Rice J; Marquet J; Rouard H; Kuentz M; Vittes GE; Molinier-Frenkel V; Farcet JP; Stauss HJ; Delfau-Larue MH; Stevenson FK
    Blood; 2008 Oct; 112(7):2956-64. PubMed ID: 18502835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.
    Borbulevych OY; Do P; Baker BM
    Mol Immunol; 2010 Sep; 47(15):2519-24. PubMed ID: 20619457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.
    Rezvani K; Brenchley JM; Price DA; Kilical Y; Gostick E; Sewell AK; Li J; Mielke S; Douek DC; Barrett AJ
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8799-807. PubMed ID: 16361568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue.
    Al Qudaihi G; Lehe C; Negash M; Al-Alwan M; Ghebeh H; Mohamed SY; Saleh AJ; Al-Humaidan H; Tbakhi A; Dickinson A; Aljurf M; Dermime S
    Leuk Lymphoma; 2009 Feb; 50(2):260-9. PubMed ID: 19197722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenic variation between multiple HLA-A*0201-restricted, Hepatitis C Virus-derived epitopes for cytotoxic T lymphocytes.
    Ohno S; Moriya O; Yoshimoto T; Hayashi H; Akatsuka T; Matsui M
    Viral Immunol; 2006; 19(3):458-67. PubMed ID: 16987064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.
    Alexander J; Oseroff C; Sidney J; Sette A
    Hum Immunol; 2003 Feb; 64(2):211-23. PubMed ID: 12559623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response.
    Sykulev Y; Joo M; Vturina I; Tsomides TJ; Eisen HN
    Immunity; 1996 Jun; 4(6):565-71. PubMed ID: 8673703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
    J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.
    Bellantuono I; Gao L; Parry S; Marley S; Dazzi F; Apperley J; Goldman JM; Stauss HJ
    Blood; 2002 Nov; 100(10):3835-7. PubMed ID: 12411326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of antigen-specific T-cell responses with synthetic peptides--what kind of peptide for which purpose?
    Kiecker F; Streitz M; Ay B; Cherepnev G; Volk HD; Volkmer-Engert R; Kern F
    Hum Immunol; 2004 May; 65(5):523-36. PubMed ID: 15172453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells.
    Müller L; Knights A; Pawelec G
    Hematol J; 2003; 4(1):57-66. PubMed ID: 12692522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.